Central European Journal of Biology

, Volume 4, Issue 1, pp 19–33 | Cite as

Anabolic androgenic steroids effects on the immune system: a review

  • Sonya Marshall-Gradisnik
  • Rachel Green
  • Ekua W. Brenu
  • Robert P. Weatherby
Review Article
  • 554 Downloads

Abstract

Androgenic anabolic steroids (AAS) are synthetic derivatives of the male hormone testosterone. AAS are used by athletes and recreational users of all ages to enhance their athletic performance and/or physical appearance. While several adverse effects of AAS abuse have been described, their effect on the immune system has not been clearly elucidated. The literature generally indicates that supraphysiologic doses of AAS with an intact steroid nucleus are immunosuppressive, that is they reduce immune cell number and function. While those with alterations to the steroid nucleus are immunostimulatory as they induce the proliferation of T cells and other immune cells. Specifically, several common AAS have been shown to adversely influence lymphocyte differentiation and proliferation, antibody production, Natural Killer Cytotoxic activity and the production of certain cytokines, thereby altering the immune reaction. These effects may be profound and long lasting depending on the dosing regime, types or combinations of AAS used and the extent and duration of AAS abuse. Nevertheless, the effects of long term use of supraphysiologic doses of AAS on the immune system remain uncertain.

Keywords

Androgenic anabolic steroids Lymphocytes Immune system Natural killer Performance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Hoberman J., Yesalis C., The history of synthetic testosterone, Scientific American 1995, 272, 76–81PubMedCrossRefGoogle Scholar
  2. [2]
    Ariel G., Saville W., Anabolic steroids: the physiological effects of placebos, Med. Sci. Sports, 1972, 4, 124–126Google Scholar
  3. [3]
    Cicero T.J., O’Connor L.H., Abuse liability of anabolic steroids and their possible role in the abuse of alcohol, morphine and other substances, In: Lin G.C., Erinoff L. (Eds.), Anabolic steroid abuse, National Institute on Drug Abuse, Rockville, 1990Google Scholar
  4. [4]
    Kadi F., Adaptation of human skeletal muscle to training and anabolic steroids, Acta Physiol. Scand. Suppl., 2000, 646, 1–52PubMedGoogle Scholar
  5. [5]
    Kadi F., Eriksson A., Holmner S., Thornell L., Effects of anabolic steroids on the muscle cells of strength trained athletes, Med. Sci. Sports. Exerc., 1999, 31, 1528–1534PubMedGoogle Scholar
  6. [6]
    Giorgi A., Weatherby R.P., Murphy P., Muscular strength, body composition and health responses to the use of testosterone enanthate: a double blind study, J. Sci. Med. Sport, 1999, 2, 341–355PubMedGoogle Scholar
  7. [7]
    Rogerson S., Weatherby R.P., Deakin G.B., Meir R.A., Coutts R.A., Zhou S., et al., The effect of short-term use of testosterone enanthate on muscular strength and power in healthy young men, J. Strength Cond. Res., 2007, 21, 354–361PubMedGoogle Scholar
  8. [8]
    van Marken Lichtenbelt W.D., Hartgens F., Vollaard N.B., Ebbing S., Kuipers H., Bodybuilders’ body composition: effect of nandrolone decanoate, Med. Sci. Sports. Exerc., 2004, 36, 484–489PubMedGoogle Scholar
  9. [9]
    Berning J.M., Adams K.J., Stamford B.A., Anabolic steroid usage in atheletics: fact, fiction, and public relations, J. Strength Cond. Res., 2004, 18, 908–917PubMedGoogle Scholar
  10. [10]
    Yesalis C.E., Use of steroids for self-enhancement: an epidemiologic/societal perspective, AIDS Read., 2001, 11, 157–160PubMedGoogle Scholar
  11. [11]
    Shah K., Montoya C., Persons R., Do testosterone injections increase libido for elderly hypogonadal patients?, J. Fam. Pract., 2007, 56, 301–305PubMedGoogle Scholar
  12. [12]
    Johnston L.D., O’Malley P.M., Bachman J.G., Schulenberg J.E., Monitoring the future national results on adolescent drug use: Overview of Key Findings, 2005, (NIH Publication No. 06-5882), National Institute on Drug Abuse, Bethesda, 2006Google Scholar
  13. [13]
    Drug Enforcement Administration, ARCOS Data for Selected Opioid Analgesics, 1980–1996, Arlington, US Dept of Justice, 1997Google Scholar
  14. [14]
    Yesalis C., Kennedy N., Kopstein A., Bahrke M., Anabolic-androgenic steroid use in the United States, JAMA, 1993, 270, 1217–1221PubMedGoogle Scholar
  15. [15]
    Hameed A., Brothwood T., Bouloux P., Delivery of testosterone replacement therapy, Curr. Opin. Invest. Drugs, 2003, 4, 1213–1219Google Scholar
  16. [16]
    Snyder P.J., Lawrence D.A., Treatment of male hypogonadism with testosterone enanthate, J. Clin. Endocrinol. Metab., 1980, 51, 1335–1339PubMedCrossRefGoogle Scholar
  17. [17]
    Ajayi A.A.L., Mathur R., Halushka P.V., Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses, Circulation, 1994, 91, 2742–2747Google Scholar
  18. [18]
    Bross R., Javanbakht M., Bhasin S., Anabolic interventions for aging associated Sarcopenia, J. Clin. Endocrinol. Metab., 1999, 84, 3420–3430PubMedGoogle Scholar
  19. [19]
    Kuhn C.M., Anabolic Steroids, Recent. Prog. Horm. Res., 2002, 57, 411–434PubMedGoogle Scholar
  20. [20]
    Pardridge W., Serum bioavailability of sex steroid hormones, Clin. Endocrinol. Metab., 1986, 15, 259–278PubMedGoogle Scholar
  21. [21]
    Rannevik G., Jeppsson S., Johnell O., Bjerre B., Laurell-Borulf Y., Svanberg L., A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density, Maturitas, 1995, 21, 103–113PubMedGoogle Scholar
  22. [22]
    Wilson J., Androgen abuse by athletes, Endocr. Rev., 1988, 9, 181–199PubMedGoogle Scholar
  23. [23]
    Bartsch W., Anabolic steroids: action on cellular level, In: Kopera H. (Ed.) Anabolic androgenic steroids towards the year 2000, Blackwell, Vienna, 1993Google Scholar
  24. [24]
    Creutzberg E., Schols A., Anabolic steroids, Curr. Opin. Clin. Nutr. Metab. Care, 1999, 2, 243–253PubMedGoogle Scholar
  25. [25]
    Horton R., Markers of peripheral androgen action in vivo and in vitro, Clin. Dermatol., 1988, 6, 46–51PubMedGoogle Scholar
  26. [26]
    Falkenstein E., Tillmann H.-C., Christ M., Feuring M., Wehling M., Multiple Actions of Steroid Hormones-A Focus on Rapid, Nongenomic Effects, Pharmacol. Rev., 2000, 52, 513–556PubMedGoogle Scholar
  27. [27]
    Beato M., Gene regulation by steroid hormones, Cell, 1989, 56, 335–344PubMedGoogle Scholar
  28. [28]
    Beato M., Klug J., Steroid hormone receptors: An update, Hum. Reprod. Update, 2000, 6, 225–236PubMedGoogle Scholar
  29. [29]
    Scheidereit C., Geisse S., Westphal H., Beato M., The glucocorticoid receptor binds to defined nucleotide sequences near the promoter of mouse mammary tumor virus, Nature (Lond.), 1983, 304, 749–752Google Scholar
  30. [30]
    Beato M., Chavez S., Truss M., Transcriptional regulation by steroid hormones, Steroids, 1996, 61, 240–251PubMedGoogle Scholar
  31. [31]
    Kindler S., Wang H., Richter D., Tiedge H., RNA transport and local control of translation, Ann. Rev. Cell Dev. Biol., 2005, 21, 223–245Google Scholar
  32. [32]
    Godowski P., Picard D., Steroid receptors. How to be both a receptor and a transcription factor, Biochem. Pharmacol., 1989, 38, 3135–3143PubMedGoogle Scholar
  33. [33]
    Chang C., Saltzman A., Yeh S., Young W., Keller E., Lee H., et al., Androgen receptor: an overview, Crit. Rev. Eukaryotic Gene. Expr., 1995, 5, 97–125Google Scholar
  34. [34]
    Wilson J., Androgens, In: Hardman J., Limbird L. (Eds.), Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed., McGraw-Hill, New York, 1996Google Scholar
  35. [35]
    Boonyaratanakornkit V., Edwards D., Receptor mechanisms mediating non-genomic actions of sex steroids, Semin. Reprod. Med., 2007, 25, 139–153PubMedGoogle Scholar
  36. [36]
    Wunderlich F., Benten W., Lieberherr M., Guo Z., Stamm O., Wrehlke C., et al., Testosterone signaling in T cells and macrophages, Steroids, 2002, 67, 535–538PubMedGoogle Scholar
  37. [37]
    Kovacs W., Olsen N., Androgen receptors in human thymocytes, J. Immunol., 1987, 139, 490–493PubMedGoogle Scholar
  38. [38]
    Benten W.P.M., Lieberherr M., Giese G., Wrehlke C., Sekeris C.E., Mossmann H., et al., Functional testosterone receptors in plasma membranes of T cells, FASEB, 1999, 13, 123–133Google Scholar
  39. [39]
    Machelon V., Nome F., Tesarik J., Nongenomic effects of androstenedione on human granulosa cells in relation to luteinization process, J. Clin. Endocrinol. Metab., 1998, 83, 263–269PubMedGoogle Scholar
  40. [40]
    Gametchu B., Watson C., Pasko D., Size and steroid binding characterisation of membrane associated glucocorticoid receptor in S49 lymphoma cells, Steroids, 1991, 56, 411–419PubMedGoogle Scholar
  41. [41]
    Wehling M., Specific, nongenomic actions of steroid hormones, Annu. Rev. Physiol., 1997, 59, 365–393PubMedGoogle Scholar
  42. [42]
    Farnsworth W., The prostate plasma membrane as an androgen receptor, Membr. Biochem., 1990 9, 141–162PubMedGoogle Scholar
  43. [43]
    Sheridan P., Can a single androgen receptor fill the bill?, Mol. Cell Endocrinol., 1991, 76, C39–C45PubMedGoogle Scholar
  44. [44]
    Lieberherr M., Grosse B., Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein, J. Biol. Chem., 1994, 269, 7217–7223PubMedGoogle Scholar
  45. [45]
    Hurd R., Testosterone, US National Library of Medicine and National Institutes of Health, Bethesda, 2006Google Scholar
  46. [46]
    Mutzebaugh C., Does the choice of alpha-AAS really make a difference?, HIV Hotline, 1998, 8, 10–11PubMedGoogle Scholar
  47. [47]
    Yamamoto Y., Moore R., Hess H., Guo G., Gonzalez F., Korach K., et al., Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity, J. Biol. Chem., 2006, 281, 16625–16631PubMedGoogle Scholar
  48. [48]
    Brodsky I., Balagopal P., Nair K., Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study, J. Clin. Endocrinol. Metab., 1996, 81, 3469–3475PubMedGoogle Scholar
  49. [49]
    Joumaa W.H., Leoty C., Differential effects of nandrolone decanoate in fast and slow rat skeletal muscles, Med. Sci. Sports Exerc., 2001, 33, 397–403PubMedGoogle Scholar
  50. [50]
    Sinha-Hikim I., Artaza J., Woodhouse L., Gonzalez-Cadavid N., Singh A., Lee M., et al., Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy, Am. J. Physiol. Endocrinol. Metab., 2002, 283, E154–E164PubMedGoogle Scholar
  51. [51]
    Berger J., Pall L., Hall C., Simpson D., Berry P, Dudley R., Oxandrolone in AIDS-wasting myopathy, AIDS, 1996, 10, 1657–1662PubMedGoogle Scholar
  52. [52]
    Hughes T.K., Fulep E., Juelich T., Smith E.M., Stanton G.J., Modulation of immune responses by anabolic androgenic steroids, Int. J. Immunopharmacol., 1995, 17, 857–863PubMedGoogle Scholar
  53. [53]
    Aribarg A., Sukcharoen N., Chanprasit Y., Ngeamvijawat J., Kriangsinyos R., Suppression of spermatogenesis by testosterone enanthate in Thai men, J. Med. Assoc. Thai.,1996, 79, 624–629PubMedGoogle Scholar
  54. [54]
    Matsumoto A., Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production, J. Clin. Endocrinol. Metab., 1990, 70, 282–287PubMedGoogle Scholar
  55. [55]
    Ballal S., Domoto D., Polack D., Marciulonis P., Martin K., Androgens potentiate the effects of erythropoietin in the treatment of anemia of endstage renal disease, Am. J. Kidney Dis., 1991, 17, 29–33PubMedGoogle Scholar
  56. [56]
    Berns J., Rudnick M., Cohen R., Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease, Am. J. Kidney Dis., 1991, 18, 143PubMedGoogle Scholar
  57. [57]
    Berns J., Rudnick M., Cohen R., A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis, Clin. Nephrol., 1992, 37, 264–267PubMedGoogle Scholar
  58. [58]
    Wu F., Farley T., Peregoudov A., Waites G., Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility, Fertil. Steril., 1996, 65, 626–636PubMedGoogle Scholar
  59. [59]
    Bhasin S., Storer T., Berman N., Callegari C., Clevenger B., Phillips J., et al., The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men, N. Engl. J. Med., 1996, 335, 1–7PubMedGoogle Scholar
  60. [60]
    Calfee R., Fadale P., Popular ergogenic drugs and supplements in young athletes, Pediatrics, 2006, 117, 577–589Google Scholar
  61. [61]
    Velazquez I., Alter B., Androgens and liver tumors: Fanconi’s anemia and non-Fanconi’s conditions, Am. J. Hematol., 2004, 77, 257–267PubMedGoogle Scholar
  62. [62]
    Strauss R., Yesalis C., Anabolic steroids and the athlete, Annu. Rev. Med., 1991, 42, 449–457PubMedGoogle Scholar
  63. [63]
    Bagatell C., Knopp R., Vale W., Rivier J., Bremner W., Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels, Ann. Intern. Med., 1992, 116, 967–973PubMedGoogle Scholar
  64. [64]
    De Piccoli B., Giada F., Benettin A., Sartori F., Piccolo E., Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function, Int. J. Sports Med., 1991, 12, 408–412PubMedGoogle Scholar
  65. [65]
    Sullivan M., Martinez C., Gallagher E., A trial fibrillation and anabolic steroids, J. Emerg. Med., 1999, 17, 851–857PubMedGoogle Scholar
  66. [66]
    Dickerman R., Schaller F., McConathy W., Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid use, Cardiology, 1998, 90, 145–148PubMedGoogle Scholar
  67. [67]
    Palacios A., McClure R., Campfield A., Swerdloff R., Effect of testosterone enanthate on testis size, J. Urol., 1981, 126, 46–48PubMedGoogle Scholar
  68. [68]
    Alén M., Androgenic steroid effects on liver and red cells, J. Sports Med., 1985, 19, 15–20Google Scholar
  69. [69]
    Marcus R., Korenman S., Estrogens and the human male, Annu. Rev. Med., 1976, 27, 357–370PubMedGoogle Scholar
  70. [70]
    Hartgens F., Kuipers H., Effects of androgenicanabolic steroids in athletes, Sports Med., 2004, 34, 513–554PubMedGoogle Scholar
  71. [71]
    Manikkam M., Crespi E., Doop D., Herkimer C., Lee J., Yu S., et al., Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep, Endocrinology, 2004, 145, 790–798PubMedGoogle Scholar
  72. [72]
    Corrigan B., Anabolic steroids and the mind, MJA, 1996, 165, 222–226PubMedGoogle Scholar
  73. [73]
    Midgley S., Heather N., Davies J., Levels of aggression among a group of anabolic-androgenic steroid users, Med. Sci. Law., 2001, 41, 309–314PubMedGoogle Scholar
  74. [74]
    Casavant M., Blake K., Griffith J., Yates A., Copley L., Consequences of use of anabolic androgenic steroids, Pediatr. Clin. North Am., 2007, 54, 677–690PubMedGoogle Scholar
  75. [75]
    Medras M., Tworowska U., Treatment strategies of withdrawal from long-term use of anabolicandrogenic steroids, Pol. Merkur. Lekarski, 2001, 11, 535–538PubMedGoogle Scholar
  76. [76]
    Kruisbeek A.M., Development of alphabeta T cells, Curr. Opin. Immunol., 1993, 5, 227–234PubMedGoogle Scholar
  77. [77]
    Abbas A.K., Murphy K.M., Sher A., Functional diversity of helper T lymphocytes, Nature, 1996, 383, 787–793PubMedGoogle Scholar
  78. [78]
    Springer T.A., Adhesion receptors of the immune system, Nature, 1990, 6, 425–434Google Scholar
  79. [79]
    Mosmann T.R., Coffman R.L., TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, Annu. Rev. Immunol., 1989, 7, 145–173PubMedGoogle Scholar
  80. [80]
    Alam R., A brief review of the immune system, Prim. Care, 1998, 25, 727–738PubMedGoogle Scholar
  81. [81]
    Medana I.M., Gallimore A., Oxzenius A., Martinic M.M., Wekerle H., Neumann H., MHC class I —restricted killing of neurons by virus-specific CD8+T lymphocytes is effected through the Fas/FasL, but not the perforin pathway, Eur. J. Immunol., 2000, 30, 3623–3633PubMedGoogle Scholar
  82. [82]
    Sutton B.J., Immunoglobulin structure and function: the interaction between antibody and antigen, Curr. Opin. Immunol., 1989, 2, 106–113PubMedGoogle Scholar
  83. [83]
    Fanning L.J., Connor A.M., Wu G.E., Development of the immunoglobulin repertoire, Clin. Immunol. Immunopathol., 1996, 79, 1–14PubMedGoogle Scholar
  84. [84]
    Ward E.S., Ghetie V., The effector function of immunoglobulins: implications for therapy, Ther. Immunol., 1995, 2, 77–94PubMedGoogle Scholar
  85. [85]
    Clark M.R., IgG effector mechanisms, Chem. Immunol., 1997, 65, 88–110PubMedGoogle Scholar
  86. [86]
    Hamerman J.A., Ogasawara K., Lainer L.L., NK cells in innate immunity, Curr Opin. Immunol., 2005, 17, 29–35PubMedGoogle Scholar
  87. [87]
    Farag S.S., Fehniger T.A., Ruggeri L., Velardi A., Caligiuri M.A., Natural killer cell receptors: new biology and insights into the graft-versus-leukaemia effect, Am. Soc. Hematol., 2002, 100, 1935–1947Google Scholar
  88. [88]
    Viver E., Tomasello E., Baratin M., Walzer T., Ugolini S., Functions of natural killer cells, Nature Immunol., 2008, 9, 503–510Google Scholar
  89. [89]
    Cooper M.A., Bush J.E., Fehniger T.A., VanDeusen J.B., Waite R.E., Liu Y., et al., In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells, Blood, 2002, 100, 3633–3638PubMedGoogle Scholar
  90. [90]
    Freud A.G., Caligiuri M.A., Human Natural Killer cell development, Immunol. Rev., 2006, 214, 56–72PubMedGoogle Scholar
  91. [91]
    Scott G.B., Meade J.L., Cook G.P., Profiling killers; unravelling the pathways of human natural killer cell function, Brief Funct. Genomic Proteomic, 2008, 7, 8–16PubMedGoogle Scholar
  92. [92]
    Dinarello C.A., Proinflammatory Cytokines, Chest, 2000, 118, 503–508PubMedGoogle Scholar
  93. [93]
    Opal S.M., DePalo V.A., Anti-inflammatory cytokines, Chest, 2000, 117, 1162–1172PubMedGoogle Scholar
  94. [94]
    Grossman C.J., Regulation of the immune system by sex steroids, Endocr. Rev., 1984, 5, 435–455PubMedGoogle Scholar
  95. [95]
    Grossman C.J., Interactions between gondal steroids and the immune system, Science, 1985, 227, 257–261PubMedGoogle Scholar
  96. [96]
    Grossman C.J., Roselle G.A., The control of immune response by endocrine factors and the clinical significance of such regulation, Prog. Clin. Biochem. Med., 1987, 4, 1–56Google Scholar
  97. [97]
    Sthoeger Z.M., Chiorazzi N., Lahita R.G., Regulation of the immune response by sex hormones: I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation, J. Immunol., 1988, 141, 91–98PubMedGoogle Scholar
  98. [98]
    Abraham A., Bug G., 3H-testosterone distribution and binding in rat thymus cells in vivo, Mol. Cell Biochem., 1976, 13, 157–163PubMedGoogle Scholar
  99. [99]
    Besedovsky H.O., Del Rey A., Immune-Neuro-Endocrine Interactions: Facts and Hypotheses, Endocr. Rev., 1996, 17, 64–102PubMedGoogle Scholar
  100. [100]
    Landmann R., Wesp M., Box R., Keller U., Buhler F., Distribution and function of beta-adrenergic receptors in human blood lymphocytes, In: Hadden J., Masek K., Nistico G. (Eds.), Interactions among CNS, Neuroendocrine and Immune Systems, Pythagora Press, Rome, 1989Google Scholar
  101. [101]
    Deschaux P., Paucod J.-C., Ardail D., Interaction between thymosin, testosterone and estradiol on natural killer cell activity in mice, Tohoku J. Exp. Med., 1982, 136, 367–372.PubMedGoogle Scholar
  102. [102]
    Fujii H., Nawa Y, Tsuchiya H., Matsuno K., Fukumoto T,. Fukuda S., et al., Effect of a single administration of testosterone on the immune response and lymphoid tissues in mice, Cell. Immunol., 1975, 20, 315–326PubMedGoogle Scholar
  103. [103]
    Mendenhall C.L., Grossman C.J., Roselle G.A., Hertelendy Z., Ghosn S.J., Lamping K., et al., Anabolic Steroid Effects on Immune Function: Differences between analogues, J. Steroid Biochem. Molec. Biol., 1990, 37, 71–76PubMedGoogle Scholar
  104. [104]
    Kotani M., Nawa Y., Fujii H., Inhibition by testosterone of immune reactivity and of lymphoid regeneration in irradiated and marrow reconstituted mice, Experientia, 1974, 30, 1343–1345PubMedGoogle Scholar
  105. [105]
    Weinstein Y., Berkovich Z., Testosterone effect on bone marrow, thymus and suppressor T cells in the (NZB x NZW) F1 mice: its relevance to autoimmunity, J. Immunol., 1981, 1126, 998–1002Google Scholar
  106. [106]
    Deschaux P., Ulrich T., Goldstein A.L., In vitro effects of thymosin, testosterone and growth hormone on antibody formation in murine spleen cells, Thymus, 1, 287–291Google Scholar
  107. [107]
    Malcolmson C., Satra C., Kantaria S., Sidhu A., Lawrence M.J., Effect of oil on the level of solubilization of testosterone propionate into oil-in-water microemulsions, J. Pharm. Sci., 1997, 87, 109–116Google Scholar
  108. [108]
    Cummings E.A., Salisbury S.R., Givner M.L., Rittmaster R.S., Testolactone-associated high androgen levels, a pharmacologic effect or a laboratory artefact?, J. Clin. Endocrinol. Metab., 1998, 83, 784–787PubMedGoogle Scholar
  109. [109]
    Rogol A.D., Yesalis C.E., Anabolic-androgenic steroids and athletes: what are the issues?, J. Clin. Endocrinol. Metab., 1992, 74, 465–469PubMedGoogle Scholar
  110. [110]
    Bouman A., Jan Heineman M., Fass M.M., Sex hormones and the immune response in humans, Hum. Reprod. Update, 2005, 11, 411–423PubMedGoogle Scholar
  111. [111]
    Lahita R.G., Sex steroids and rheumatic disease, Arthritis Rheum., 1985, 28, 121–126PubMedGoogle Scholar
  112. [112]
    Hirota Y., Suzuki T., Chayano Y., Bito Y., Humoral immune responses characteristic of testosterone-propionate-treated chickens, Immunology, 1976, 30, 341–348PubMedGoogle Scholar
  113. [113]
    Olsen N.J., Kovacs W.J., Gonadal steroids and immunity, Endocr. Rev., 1996, 17, 369–384PubMedGoogle Scholar
  114. [114]
    Paavonen T., Hormonal regulation of immune responses, Ann. Med., 1994, 26, 255–258PubMedGoogle Scholar
  115. [115]
    Schuurs A.H., Verheul A.M., Schot L., Experimental work with anabolics in autoimmunity models, Acta Physiol., 1985, 271, 97–107Google Scholar
  116. [116]
    Schuurs A.H., Verheul H.A.M., Effects of gender and sex steroids on the immune response, J. Steroid Biochem., 1990, 35, 157–172PubMedGoogle Scholar
  117. [117]
    Calabrese L.H., Kleiner S.M., Barna B.P., Skibinski C.I, Kirkendall D.T., Lahita R.G., et al., The effects of anabolic steroids and strength training on the human immune response, Med. Sci. Sport Exerc., 1989, 21, 386–392Google Scholar
  118. [118]
    Siiteri P., Stites D., Immunologic and endocrine interrelationships in pregnancy, Biol. Reprod., 1982, 26, 1–14PubMedGoogle Scholar
  119. [119]
    Siiteri P.K., Jones L.A., Roubinian J.R., Talal N.K., Sex steroids and the immune system: I. Sex difference in autoimmune disease in NZB/NZW hybrid mice, J. Steroid Biochem., 1980, 12, 425–432PubMedGoogle Scholar
  120. [120]
    Sulke A.N., Jones D.B., Wood P.J., Hormonal modulation of human natural killer cell activity in vitro, J. Reprod Immunol., 1985, 7, 105–110PubMedGoogle Scholar
  121. [121]
    Wyle F., Kent J., Immunosuppresion by sex steroid hormones. I. The effect upon PHA and PPD stimulated lymphocytes, Clin. Exp. Immunol., 1977, 27, 407–415PubMedGoogle Scholar
  122. [122]
    Kanda N., Tsuchida T., Tamaki K., Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells, Clin. Exp. Immunol., 1996, 106, 410–415PubMedGoogle Scholar
  123. [123]
    Olsen N., Kovacs W., Effects of androgens on T and B lymphocyte development, Immunol. Res., 2001, 23, 281–288PubMedGoogle Scholar
  124. [124]
    Hinterberger W., Vierhapper H., Anabolic steroids and blood cell production, Wien Med. Wochenschr., 1993, 143, 380–382PubMedGoogle Scholar
  125. [125]
    Hervey G., Hutchinson I., Knibbs A., Burkinshaw L., Jones P., Norgan N., et al., “Anabolic” effects of methandienone in men undergoing athletic training, Lancet, 1976, 2, 699–702PubMedGoogle Scholar
  126. [126]
    Hervey G., Knibbs A., Burkinshaw L., Morgan D., Jones P., Chettle D., et al., Effects of methandienone on the performance and body composition of men undergoing athletic training, Clin. Sci. (Lond.), 1981, 60, 457–461Google Scholar
  127. [127]
    Johnson L., Roundy E., Allsen P., Fisher A., Silvester L., Effect of anabolic steroid treatment on endurance, Med. Sci. Sports., 1975, 7, 287–289PubMedGoogle Scholar
  128. [128]
    Stromme S., Meen H., Aakvaag A., Effects of an androgenic-anabolic steroid on strength development and plasma testosterone levels in normal males, Med. Sci. Sports, 1974, 6, 203–208PubMedGoogle Scholar
  129. [129]
    Win-May M., Mya-Tu M., The effect of anabolic steroids on physical fitness, J. Sports Med. Phys. Fitness, 1975, 15, 266–271PubMedGoogle Scholar
  130. [130]
    Alén M., Reinilä M., Vihko R., Response of serum hormones to androgen administration in power athletes, Med. Sci. Sports Exerc., 1985, 17, 354–359PubMedGoogle Scholar
  131. [131]
    Hartgens F., Hamulyak K., Pernot C., Willems S.M., Effects of high doses androgenic-anabolic steroids on haematoglic parameters in bodybuilders, In: 8th FIMS European Sports Medicine Congress, Granada, 1995Google Scholar
  132. [132]
    Callewaert D.M., Moudgil V.K., Radcliff G., Waite R., Hormone specific regulation of natural killer cells by cortisol: Direct inactivation of the cytotoxic function of cloned human NK cells without an effect on cellular proliferation, FEBS Lett., 1991, 285, 108–110PubMedGoogle Scholar
  133. [133]
    Marshall-Gradisnik S., Rogerson S., Zhou S., Coutts R., Meir R. Deakin G., et al., A reduction in natural killer cell cytotoxic activity after six weeks of testosterone administration, J. Exerc. Sci. Fitness., 2008, 6, 142–151Google Scholar
  134. [134]
    Zajac A., Jarzabek R., Waskiewicz Z., The diagnostic value of the 10- and 30-second Wingate test for competitive athletes, J. Strength Cond. Res., 1999, 13, 16–19Google Scholar
  135. [135]
    Huber S., Job L., Auld K., Influence of sex hormones on Coxsackie B-3 virus infection in Balb/c mice, Cell. Immunol., 1982, 67, 173–189PubMedGoogle Scholar
  136. [136]
    Araneo B.A., Dowell T., Diegel M., Daynes R.A., Dihydrotestosterone exerts a depressive influence on the productioni of interleukin-4 (IL-4), IL-5, and gamma interferon, but not IL-2 by activated murine T cells, Blood, 1991, 78, 688–699PubMedGoogle Scholar
  137. [137]
    Shephard R.J, Rhind S., Shek P.N., Exercise and the immune system: natural killer cells, interleukins and related responses, Sports Med., 1994, 18, 340–369PubMedGoogle Scholar
  138. [138]
    Suzuki R., Handa K., Itoh K., Kumagai K., Natural killer cells (NK) as a responder to interleukin-2 (IL-2), I: proliferative response and establishment of cloned cells, J. Immunol., 1983, 130, 981–987PubMedGoogle Scholar
  139. [139]
    Graham H., Douglas R., Ryan P., Stress and acute respiratory infection, Am. J. Epidemiol., 1986, 124, 389–401PubMedGoogle Scholar
  140. [140]
    Nagao F., Suzuki M., Taeda K., Yagita H., Okumura K., Mobilisation of NK cells by exercise: down modulation of adhesion molecules on NK cells by catecholamines, Am. J. Physiol., 2000, 289, R1251–R1256Google Scholar
  141. [141]
    Nagler A., Lainer L., Phillips J., Constitutive expression of high affinity IL-2 receptors on human CD16 natural killer cells in vivo, J. Exp. Med., 1990, 171, 1527–1533PubMedGoogle Scholar
  142. [142]
    Menard C., Harlan R., Up-regulation of androgen receptor immunoreactivity in the rat brain by androgenic-anabolic steroids, Brain Res., 1993, 622, 226–236PubMedGoogle Scholar
  143. [143]
    Hughes T.K., Rady P.L., Smith E.M., Potential for the effects of anabolic steroid abuse in the immune and neuroendocrine axis, J. Neuroimmunol., 1998, 83, 162–167PubMedGoogle Scholar
  144. [144]
    World Anti-Doping Agency. The World Anti-Doping Code, The 2008 prohibited list, 2008, http://www.wada-ama.org/rtecontent/document/2008_List_En.pdf
  145. [145]
    Kicman A.T., Pharmacology of anabolic steroids, Br. J. Pharmacol., 2008, 154, 502–521PubMedGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Sonya Marshall-Gradisnik
    • 1
  • Rachel Green
    • 1
  • Ekua W. Brenu
    • 1
  • Robert P. Weatherby
    • 2
  1. 1.Faculty of Health Science and MedicineBond UniversityRobinaAustralia
  2. 2.Department of Exercise Science and Sport ManagementSouthern Cross UniversityLismoreAustralia

Personalised recommendations